Analysts Issue Forecasts for TSHA FY2025 Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Taysha Gene Therapies in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings per share of ($0.40) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 price target on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share.

A number of other equities analysts also recently weighed in on TSHA. JMP Securities reissued a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research note on Monday, January 6th. Canaccord Genuity Group raised their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Finally, Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $1.53 on Wednesday. Taysha Gene Therapies has a 1 year low of $1.19 and a 1 year high of $4.32. The company has a market capitalization of $313.56 million, a PE ratio of 2.43 and a beta of 0.95. The business has a fifty day moving average price of $2.10 and a two-hundred day moving average price of $2.09. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Creative Planning bought a new position in shares of Taysha Gene Therapies in the third quarter worth $28,000. China Universal Asset Management Co. Ltd. boosted its stake in Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after purchasing an additional 17,446 shares during the period. Privium Fund Management B.V. grew its holdings in Taysha Gene Therapies by 21.8% during the 3rd quarter. Privium Fund Management B.V. now owns 120,000 shares of the company’s stock valued at $241,000 after buying an additional 21,500 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Taysha Gene Therapies by 7.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock valued at $930,000 after buying an additional 33,123 shares during the period. Finally, MetLife Investment Management LLC lifted its holdings in shares of Taysha Gene Therapies by 81.9% in the third quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock worth $153,000 after buying an additional 34,243 shares in the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.